The clinical laboratory instrumentation (CLI) market in Taiwan is a mature market that is approaching saturation. Taiwan has one of the best healthcare systems in Asia Pacific after Japan and offers both modern and comprehensive medical services to its population. The CLI market in Taiwan was valued at approximately $67.0 million in 2005 and is expected to grow by about 4.0 percent in 2006. The market is expected to experience of compound annual growth rate (CAGR) of 5.9 percent driven by strong growth in molecular diagnostics product segment. Growth in core market segments of clinical chemistry, immunochemistry and hematology remain modest with growth expected to pick up towards the end of the forecast period.